ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.102,15
0,75%
S&P 500
5.930,85
1,09%
US Dollar vs BRL
6,086
0,00%
Bitcoin
97.552,96
-0,21%
Brent Oil
72,72
0,00%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Amgen Inc (AMGN)

  7. Amgen Inc (AMGN) Notícias

AMGN

Amgen (AMGN)

Amgen Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AMGN
DataHoraFonteTítuloCódigoCompanhia
10/12/202418:30PR Newswire (US)AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDENDNASDAQ:AMGNAmgen Inc
07/12/202412:00PR Newswire (US)BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)NASDAQ:AMGNAmgen Inc
06/12/202420:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/12/202411:00PR Newswire (US)AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINANASDAQ:AMGNAmgen Inc
02/12/202418:00PR Newswire (US)AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
29/11/202418:30PR Newswire (US)AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCENASDAQ:AMGNAmgen Inc
26/11/202409:05PR Newswire (US)AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDYNASDAQ:AMGNAmgen Inc
26/11/202409:00PR Newswire (US)AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAMNASDAQ:AMGNAmgen Inc
20/11/202418:00PR Newswire (US)AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENTNASDAQ:AMGNAmgen Inc
14/11/202418:00PR Newswire (US)AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024NASDAQ:AMGNAmgen Inc
13/11/202417:27PR Newswire (US)MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRMNASDAQ:AMGNAmgen Inc
13/11/202407:00PR Newswire (US)AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATANASDAQ:AMGNAmgen Inc
08/11/202418:00PR Newswire (US)AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
08/11/202404:00PR Newswire (US)TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPSNASDAQ:AMGNAmgen Inc
31/10/202408:13IH Market NewsMicrosoft and Meta Decline Up to 4%; Roku Falls 14% Amid Lower Estimates; Booking Surges 6%; Carvana Soars 20%NASDAQ:AMGNAmgen Inc
30/10/202417:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMGNAmgen Inc
30/10/202417:01PR Newswire (US)AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTSNASDAQ:AMGNAmgen Inc
25/10/202417:00PR Newswire (US)AMGEN ANNOUNCES 2024 FOURTH QUARTER DIVIDENDNASDAQ:AMGNAmgen Inc
24/10/202417:00PR Newswire (US)AMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTSNASDAQ:AMGNAmgen Inc
15/10/202409:00PR Newswire (US)AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024NASDAQ:AMGNAmgen Inc
01/10/202410:00PR Newswire (US)LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFENASDAQ:AMGNAmgen Inc
25/09/202417:45IH Market NewsDow, S&P Come Off Record Highs, Close On Weak NoteNASDAQ:AMGNAmgen Inc
24/09/202417:00PR Newswire (US)TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASENASDAQ:AMGNAmgen Inc
23/09/202417:00PR Newswire (US)AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASENASDAQ:AMGNAmgen Inc
13/09/202410:00PR Newswire (US)AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024NASDAQ:AMGNAmgen Inc
09/09/202410:00PR Newswire (US)AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024NASDAQ:AMGNAmgen Inc
30/08/202417:00PR Newswire (US)AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
29/08/202417:00PR Newswire (US)AMGEN TO PRESENT AT THE MORGAN STANLEY 22ND ANNUAL GLOBAL HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
23/08/202417:20Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AMGNAmgen Inc
20/08/202410:00PR Newswire (US)OTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASISNASDAQ:AMGNAmgen Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:AMGN

Seu Histórico Recente

BOV
FICT3
Fictor Alimentos
BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
TELB4
TELEBRAS PN
BOV
HBOR3
HELBOR ON
BOV
ENGI11
ENERGISA
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados